Recently Featured

Clinical Trials Often Exclude Patients with Rare Diseases, Highlighting a Critical Gap

February 16, 2026
Families grappling with rare diseases often find that clinical trials, designed to test new therapies, are frequently inaccessible to them. This reality is underscored by the experience of families like mine, as I navigate the complexities of my granddaughter’s condition, Dravet syndrome, a severe form of epilepsy linked to genetic mutations. Dravet syndrome, primarily caused…

Eli Lilly Commits Up to $11.25B to Expand Oncology and Immunology Pipelines

February 16, 2026
Eli Lilly has announced significant investments aimed at bolstering its oncology and immunology pipelines, committing up to $11.25 billion through two major deals. The pharmaceutical giant will acquire Orna Therapeutics for $2.4 billion, focusing on innovative in vivo chimeric antigen receptor (CAR) T-cell therapies for autoimmune diseases and cancers. Additionally, Lilly has entered a collaboration…

Gilead’s Shares Decline Despite Strong Earnings Amid High Expectations for Yeztugo

February 16, 2026
Gilead Sciences experienced a notable drop in its stock price, falling as much as 6% in after-hours trading following the release of its earnings report. This decline has been attributed to concerns that the market’s expectations for Yeztugo, Gilead’s new HIV drug, may be overly optimistic and not aligned with its current performance trajectory. Contextually,…

Automated Workflows and Partnerships Lead Omega Bio-tek’s SLAS 2026 Announcements

February 15, 2026
As laboratories push for higher throughput, greater reproducibility, and more automation-ready workflows, the industry is increasingly turning to collaboration to solve persistent bottlenecks. Omega Bio-tek is leaning into that shift. At the 2026 SLAS International Conference & Exhibition, the company is debuting several partnerships designed to streamline nucleic acid purification across a wide range of…

Ongoing Cases